Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

723 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Discovery and in vitro and in vivo profiles of 4-fluoro-N-[4-[6-(isopropylamino)pyrimidin-4-yl]-1,3-thiazol-2-yl]-N-methylbenzamide as novel class of an orally active metabotropic glutamate receptor 1 (mGluR1) antagonist.
Satoh A, Nagatomi Y, Hirata Y, Ito S, Suzuki G, Kimura T, Maehara S, Hikichi H, Satow A, Hata M, Ohta H, Kawamoto H. Satoh A, et al. Among authors: suzuki g. Bioorg Med Chem Lett. 2009 Sep 15;19(18):5464-8. doi: 10.1016/j.bmcl.2009.07.097. Epub 2009 Jul 23. Bioorg Med Chem Lett. 2009. PMID: 19674894
Discovery and biological profile of isoindolinone derivatives as novel metabotropic glutamate receptor 1 antagonists: a potential treatment for psychotic disorders.
Ito S, Hirata Y, Nagatomi Y, Satoh A, Suzuki G, Kimura T, Satow A, Maehara S, Hikichi H, Hata M, Ohta H, Kawamoto H. Ito S, et al. Among authors: suzuki g. Bioorg Med Chem Lett. 2009 Sep 15;19(18):5310-3. doi: 10.1016/j.bmcl.2009.07.145. Epub 2009 Aug 3. Bioorg Med Chem Lett. 2009. PMID: 19692242
Pharmacological characterization of a new, orally active and potent allosteric metabotropic glutamate receptor 1 antagonist, 4-[1-(2-fluoropyridin-3-yl)-5-methyl-1H-1,2,3-triazol-4-yl]-N-isopropyl-N-methyl-3,6-dihydropyridine-1(2H)-carboxamide (FTIDC).
Suzuki G, Kimura T, Satow A, Kaneko N, Fukuda J, Hikichi H, Sakai N, Maehara S, Kawagoe-Takaki H, Hata M, Azuma T, Ito S, Kawamoto H, Ohta H. Suzuki G, et al. J Pharmacol Exp Ther. 2007 Jun;321(3):1144-53. doi: 10.1124/jpet.106.116574. Epub 2007 Mar 14. J Pharmacol Exp Ther. 2007. PMID: 17360958
Pharmacological effects of the metabotropic glutamate receptor 1 antagonist compared with those of the metabotropic glutamate receptor 5 antagonist and metabotropic glutamate receptor 2/3 agonist in rodents: detailed investigations with a selective allosteric metabotropic glutamate receptor 1 antagonist, FTIDC [4-[1-(2-fluoropyridine-3-yl)-5-methyl-1H-1,2,3-triazol-4-yl]-N-isopropyl-N-methyl-3,6-dihydropyridine-1(2H)-carboxamide].
Satow A, Maehara S, Ise S, Hikichi H, Fukushima M, Suzuki G, Kimura T, Tanak T, Ito S, Kawamoto H, Ohta H. Satow A, et al. Among authors: suzuki g. J Pharmacol Exp Ther. 2008 Aug;326(2):577-86. doi: 10.1124/jpet.108.138107. Epub 2008 May 16. J Pharmacol Exp Ther. 2008. PMID: 18487514
Unique antipsychotic activities of the selective metabotropic glutamate receptor 1 allosteric antagonist 2-cyclopropyl-5-[1-(2-fluoro-3-pyridinyl)-5-methyl-1H-1,2,3-triazol-4-yl]-2,3-dihydro-1H-isoindol-1-one.
Satow A, Suzuki G, Maehara S, Hikichi H, Murai T, Murai T, Kawagoe-Takaki H, Hata M, Ito S, Ozaki S, Kawamoto H, Ohta H. Satow A, et al. Among authors: suzuki g. J Pharmacol Exp Ther. 2009 Jul;330(1):179-90. doi: 10.1124/jpet.109.151118. Epub 2009 Apr 9. J Pharmacol Exp Ther. 2009. PMID: 19359526
723 results